Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $281,800.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $28.18, for a total value of $281,800.00. Following the completion of the sale, the chief operating officer now directly owns 226,286 shares of the company’s stock, valued at approximately $6,376,739.48. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jonathan Young also recently made the following trade(s):

• On Tuesday, September 10th, Jonathan Young sold 568 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total transaction of $14,870.24.
• On Thursday, August 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.75, for a total transaction of $133,750.00.

Akero Therapeutics Price Performance

Shares of Akero Therapeutics stock opened at $28.24 on Friday. Akero Therapeutics, Inc. has a twelve month low of $11.25 and a twelve month high of $50.42. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. The firm has a market cap of $1.95 billion, a P/E ratio of -8.83 and a beta of -0.25. The firm’s 50-day simple moving average is $26.53 and its 200-day simple moving average is $23.91.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.09. As a group, research analysts expect that Akero Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

Institutional Trading of Akero Therapeutics

Large investors have recently made changes to their positions in the business. Handelsbanken Fonder AB grew its stake in shares of Akero Therapeutics by 12.4% during the third quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock valued at $574,000 after purchasing an additional 2,200 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in Akero Therapeutics by 8.1% during the 2nd quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock worth $35,188,000 after buying an additional 112,426 shares in the last quarter. Long Focus Capital Management LLC boosted its position in Akero Therapeutics by 119.0% in the 2nd quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company’s stock valued at $16,882,000 after buying an additional 391,000 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Akero Therapeutics by 26.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 107,172 shares of the company’s stock valued at $2,514,000 after buying an additional 22,195 shares during the period. Finally, Ensign Peak Advisors Inc raised its position in shares of Akero Therapeutics by 2.1% during the second quarter. Ensign Peak Advisors Inc now owns 237,494 shares of the company’s stock worth $5,572,000 after acquiring an additional 4,950 shares during the last quarter.

Wall Street Analysts Forecast Growth

AKRO has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Akero Therapeutics in a report on Tuesday, September 17th. Wolfe Research began coverage on Akero Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Akero Therapeutics in a report on Thursday, June 20th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.13.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.